ArticleThe American journal of case reports2025
Management of Rheumatoid Arthritis in a Patient with Aplastic Anemia and Ulcerative Colitis: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Rheumatoid arthritis (RA) is a prevalent systemic autoimmune disease characterized by chronic inflammatory arthritis and extra-articular involvement. Managing RA in patients with concurrent hematologic disorders, such as aplastic anemia, presents unique therapeutic challenges due to the immunosuppressive effects of disease-modifying antirheumatic drugs (DMARDs). This case report highlights a multidisciplinary approach to the complex treatment of RA in a patient with aplastic anemia and ulcerative colitis. CASE REPORT A woman in her early 50s with a history of ulcerative colitis and aplastic anemia presented with worsening inflammatory arthritis and was diagnosed with rheumatoid arthritis (RA). Hydroxychloroquine was initially selected over methotrexate due to its relatively lower risk of bone marrow suppression, an important consideration in patients with underlying aplastic anemia. However, despite its relatively favorable hematologic safety profile, the patient developed thrombocytopenia on hydroxychloroquine, necessitating its discontinuation. Sarilumab was introduced but led to recurrent anemia and thrombocytopenia. A transition to IV tocilizumab resulted in clinical stability and symptom control. Inflammatory markers remain within normal limits, indicating no active inflammation. However, the patient continues to have thrombocytopenia and anemia, requiring ongoing hematologic monitoring. CONCLUSIONS This case underscores the complexity of RA management in patients with serious hematologic conditions. Tocilizumab proved to be an effective and well-tolerated treatment option, demonstrating the importance of individualized therapy and close hematologic monitoring. Further research is needed to optimize treatment strategies for RA in patients with concurrent aplastic anemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.